Opioid Withdrawal Syndrome Market Insight, Epidemiology, and Market Forecast – 2034
Opioid Withdrawal Syndrome (OWS) is a major public health concern caused by the sudden reduction or cessation of opioids in dependent individuals. Symptoms like anxiety, cramps, and severe cravings make withdrawal a key barrier to recovery. With the ongoing opioid crisis, the demand for effective, accessible treatments continues to grow.
DelveInsight's ' Opioid Withdrawal Syndrome Market Report ' offers a detailed analysis of the current and projected landscape for OWS treatment across the major markets, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report outlines the evolving epidemiology, highlighting the high prevalence of opioid dependence and withdrawal cases, particularly in countries severely impacted by opioid misuse. It also examines standard clinical practices and treatment gaps, providing a strategic overview of the healthcare burden and future market potential.
Current treatment regimens for OWS typically involve a combination of opioid agonists such as buprenorphine and methadone, non-opioid medications like clonidine and lofexidine, and supportive symptom-based therapies. While effective to some extent, these approaches often face challenges related to tolerability, relapse risk, and access to care. The approval of non-opioid therapies like Lucemyra (lofexidine hydrochloride) has expanded options for managing withdrawal symptoms, but broader therapeutic innovation remains limited. Newer candidates in clinical development are targeting novel pathways to reduce withdrawal intensity and improve adherence during detoxification.
With rising investments in addiction research, increasing awareness around opioid misuse, and supportive policy reforms in many countries, the OWS treatment market is set to evolve significantly by 2034. DelveInsight's report captures this transformation by evaluating market dynamics, key players, emerging therapies, and regulatory landscapes. It is an essential resource for pharmaceutical companies, healthcare providers, policymakers, and investors looking to understand and capitalize on the opportunities in this high-need therapeutic area.
Some of the Key Facts of the Opioid Withdrawal Syndrome Market Report:
• In 2022, the Opioid Withdrawal Syndrome market in the 7MM was valued at around USD 1.3 billion and is expected to grow steadily through 2034.
• Approximately 8.2 million cases of opioid withdrawal syndrome were reported in the 7MM in 2022, with a projected decline over the forecast period.
• Around 9.1 million individuals had long-term opioid use in the 7MM in 2022.
• The US accounted for nearly 7.1 million opioid withdrawal cases in 2022, expected to decrease by 2034.
• In March 2025, Hikma Pharmaceuticals announced that Health Canada approved KLOXXADO® (naloxone HCl) Nasal Spray 8 mg for the treatment of known or suspected opioid overdose, characterized by respiratory and/or central nervous system depression, in adult patients.
• In February 2025, Indivior announced that the FDA approved label changes for SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The updates include a rapid initiation protocol reducing treatment time from one week to one hour and alternative injection sites to improve flexibility and patient adherence.
• In October 2024, the FDA approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone IR 10 mg) for severe pain management. It is the first FDA-approved abuse-deterrent IR oxycodone designed to reduce intranasal and intravenous misuse.
• Leading companies in the Opioid Withdrawal Syndrome market include atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others.
• Emerging acute Opioid Withdrawal Syndrome drugs include BXCL501, MN-166, DMX-1002, and others.
• Opioid Withdrawal Syndrome remains a significant clinical challenge, with rising awareness and evolving treatment strategies driving demand for safer, more effective therapies to manage symptoms and reduce relapse risk.
To know in detail about the Opioid Withdrawal Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Opioid Withdrawal Syndrome Market Forecast
Opioid Withdrawal Syndrome Overview
Opioid Withdrawal Syndrome (OWS) is a clinical condition that occurs when individuals who are physically dependent on opioids suddenly reduce or discontinue their use. This syndrome is a hallmark of opioid dependence and is driven by the neuroadaptive changes in the brain that result from prolonged exposure to opioids. When opioid use is stopped, the abrupt absence of the drug leads to a rebound of neurotransmitter activity, particularly within the noradrenergic and dopaminergic systems, triggering a range of distressing physical and psychological symptoms.
Symptoms of opioid withdrawal typically begin within hours of the last dose and can vary in intensity depending on the type of opioid used, duration of use, and individual factors such as tolerance and overall health. Common early symptoms include anxiety, agitation, muscle aches, sweating, and insomnia. These may progress to more severe manifestations such as abdominal cramps, vomiting, diarrhea, dilated pupils, rapid heartbeat, and intense cravings. While not usually life-threatening, the severity of symptoms can lead to significant discomfort and increase the risk of relapse.
Get a free sample of the Opioid Withdrawal Syndrome market report with key insights and emerging therapies here:
Opioid Withdrawal Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Opioid Withdrawal Syndrome Epidemiology Segmentation:
The Opioid Withdrawal Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Number of Opioid Misuse Cases
• Number of Cases with long term Opioid usage
• Total Opioid Withdrawal symptoms Cases
Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Epidemiology Forecast
Opioid Withdrawal Syndrome Drugs Uptake and Pipeline Development Activities
The Opioid Withdrawal Syndrome drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Opioid Withdrawal Syndrome market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the Opioid Withdrawal Syndrome pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Opioid Withdrawal Syndrome Market Outlook
The Opioid Withdrawal Syndrome (OWS) market is expected to witness steady growth through 2034, driven by the increasing prevalence of opioid use disorder (OUD), rising awareness about withdrawal management, and expanding access to treatment services. As the opioid crisis continues to pose a significant public health burden across the globe, particularly in the United States and parts of Europe, the demand for effective withdrawal therapies is accelerating. The availability of both opioid-based and non-opioid pharmacological options, including buprenorphine and clonidine, is enhancing treatment outcomes and reducing relapse rates, contributing to market expansion.
Furthermore, advancements in withdrawal management protocols, growing governmental and private sector investments in addiction care, and the development of more targeted and patient-friendly therapeutics are fueling innovation in the OWS treatment landscape. The emergence of new formulations, such as long-acting buprenorphine and novel non-opioid agents, is expected to diversify the treatment arsenal and improve patient adherence. With continued efforts toward destigmatization and the integration of mental health support, the OWS market is poised for sustained progress over the forecast period.
Opioid Withdrawal Syndrome Market Strengths
• Increased global awareness about the opioid crisis, coupled with supportive government policies, funding, and public health initiatives, has significantly strengthened the market. Programs promoting medication-assisted treatment (MAT) and opioid withdrawal management have expanded access to care, thereby boosting demand for therapeutic options.
• The development of innovative pharmacological treatments, such as non-opioid medications (e.g., lofexidine) and extended-release formulations of buprenorphine, has improved treatment adherence and outcomes. These advancements enhance patient experience and create opportunities for differentiated products in the market.
Opioid Withdrawal Syndrome Market Weaknesses
• Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment.
• Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment.
Scope of the Opioid Withdrawal Syndrome Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Opioid Withdrawal Syndrome Companies: atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others.
• Key Opioid Withdrawal Syndrome Therapies: BXCL501, MN-166, DMX-1002, and others.
• Opioid Withdrawal Syndrome Therapeutic Assessment: Opioid Withdrawal Syndrome, currently marketed, and Opioid Withdrawal Syndrome emerging therapies
• Opioid Withdrawal Syndrome Market Dynamics: Opioid Withdrawal Syndrome market drivers and Opioid Withdrawal Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Opioid Withdrawal Syndrome Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal Syndrome Market Access and Reimbursement
To learn more about the key players and advancements in the Opioid Withdrawal Syndrome treatment landscape, visit the Opioid Withdrawal Syndrome Market Analysis Report
Table of Contents
1. Opioid Withdrawal Syndrome Market Report Introduction
2. Executive Summary for Opioid Withdrawal Syndrome
3. SWOT analysis of Opioid Withdrawal Syndrome
4. Opioid Withdrawal Syndrome Patient Share (%) Overview at a Glance
5. Opioid Withdrawal Syndrome Market Overview at a Glance
6. Opioid Withdrawal Syndrome Disease Background and Overview
7. Opioid Withdrawal Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Opioid Withdrawal Syndrome
9. Opioid Withdrawal Syndrome Current Treatment and Medical Practices
10. Opioid Withdrawal Syndrome Unmet Needs
11. Opioid Withdrawal Syndrome Emerging Therapies
12. Opioid Withdrawal Syndrome Market Outlook
13. Country-Wise Opioid Withdrawal Syndrome Market Analysis (2020–2034)
14. Opioid Withdrawal Syndrome Market Access and Reimbursement of Therapies
15. Opioid Withdrawal Syndrome Market Drivers
16. Opioid Withdrawal Syndrome Market Barriers
17. Opioid Withdrawal Syndrome Appendix
18. Opioid Withdrawal Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 hours ago
- Globe and Mail
PD-L1 Inhibitors Market Insight, Epidemiology, and Market Forecast – 2034
PD-L1 inhibitors have become a vital part of modern cancer therapy by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. By restoring T-cell function, these therapies boost the body's ability to fight cancer. They have shown significant clinical benefit, including durable responses and improved survival, in several cancers such as NSCLC, TNBC, renal cell carcinoma, urothelial carcinoma, and head and neck squamous cell carcinoma. DelveInsight's ' PD-L1 Inhibitors Market Report ' provides an in-depth analysis of the current and future market landscape for PD-L1 inhibitors across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and other key geographies. The report offers comprehensive epidemiological insights, treatment algorithms, evolving biomarker trends, and the competitive environment surrounding PD-L1-targeting therapies. Currently marketed PD-L1 inhibitors, including TECENTRIQ, IMFINZI, and BAVENCIO, have expanded their indications through successful regulatory approvals. These agents are widely used as monotherapy or in combination with chemotherapy, anti-VEGF agents, or other immune checkpoint inhibitors, depending on cancer type and biomarker expression. The market is witnessing dynamic growth driven by increasing PD-L1 biomarker testing, expanded indications, strategic collaborations, and next-generation immuno-oncology research. The development pipeline includes novel PD-L1 inhibitors, bispecific antibodies, and combination regimens aimed at overcoming resistance and improving patient outcomes. Companies such as EQRx, CStone Pharmaceuticals, Pfizer, Novartis, and others are leading the field with continuous investment in clinical trials and label expansions. However, challenges persist, including the identification of optimal biomarkers for patient selection, immune-related adverse events, resistance mechanisms, and cost-effectiveness concerns. Despite these hurdles, the PD-L1 inhibitor market is expected to grow substantially through 2034, supported by ongoing innovations, broader clinical acceptance, and rising global cancer burden. This report serves as a vital resource for pharmaceutical companies, investors, clinical researchers, and oncologists looking to navigate the evolving PD-L1 inhibitor landscape, assess market opportunities, and drive strategic decision-making. Some of the Key Facts of the PD-L1 Inhibitors Market Report: • In 2023, the PD-L1 inhibitors market size in the 7MM was approximately USD 36 billion, with the United States contributing the largest share. • Key indications in the U.S. (2023 incident cases): • KEYTRUDA and OPDIVO, the leading PD-L1 inhibitors, are expected to lose patent exclusivity in the U.S. by 2028, potentially impacting market dynamics. • The loss of exclusivity may lead to a market decline, as biosimilars emerge and new entrants may struggle to match the current dominance of KEYTRUDA and OPDIVO, even with approvals in multiple indications. • Clinical trial activity has surged, over 4,400 trials registered, with more than 3,600 ongoing. • Around 90% of new trials since 2020 are exploring PD-L1 inhibitors in combination regimens, highlighting a strong shift towards combination strategies. • In April 2025, Gilead Sciences reported positive results from the Phase III ASCENT-04/KEYNOTE-D19 study, showing that the combination of TRODELVY (sacituzumab govitecan-hziy) and KEYTRUDA (pembrolizumab) significantly improved progression-free survival in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10), compared to chemotherapy and KEYTRUDA alone. • In March 2025, the FDA granted traditional approval for frontline pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy (fluoropyrimidine- and platinum-based) for adults with locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) of at least 1 (CPS ≥1). • In March 2025, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). • In February 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to nogapendekin alfa (Anktiva) and CAR-NK (PD-L1 t-haNK) for their potential to reverse lymphopenia in patients undergoing chemotherapy/radiotherapy and to treat metastatic pancreatic cancer. • In February 2025, Beijing Biostar Pharmaceuticals announced that its Utidelone Capsules, in combination with capecitabine and oxaliplatin, received FDA approval for a Phase II/III registration clinical study (BG02-2404). This Combination Therapy is for first-line treatment of PD-L1-negative, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. • In January 2025, the FDA approved tislelizumab, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the first-line treatment of patients with unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). • Leading companies in the PD-L1 Inhibitors market include EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Emerging acute PD-L1 inhibitor drugs include Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 inhibitors are reshaping cancer care, fueling demand for more targeted and durable treatment options across multiple tumor types with growing clinical adoption and expanding indications. To know in detail about the PD-L1 Inhibitors market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: PD-L1 Inhibitors Overview Programmed death-ligand 1 (PD-L1) inhibitors are a class of immune checkpoint inhibitors that have revolutionized cancer immunotherapy by enhancing the body's natural ability to fight tumors. PD-L1 is a protein expressed on tumor cells and tumor-infiltrating immune cells that binds to the PD-1 receptor on T-cells, effectively turning off the immune response. By blocking this interaction, PD-L1 inhibitors restore T-cell activity, allowing the immune system to recognize and destroy cancer cells more effectively. PD-L1 inhibitors are currently approved for a variety of malignancies, including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer (TNBC), hepatocellular carcinoma, and others. Some of the key PD-L1 inhibitors include atezolizumab (TECENTRIQ), durvalumab (IMFINZI), and avelumab (BAVENCIO). These therapies are often used either as monotherapy or in combination with chemotherapy, targeted therapy, or other immunotherapies. Ongoing research continues to expand its applications across tumor types and disease stages, and the development of predictive biomarkers aims to refine patient selection for optimal treatment outcomes. With multiple agents in clinical and preclinical development, PD-L1 inhibitors remain a cornerstone of immuno-oncology, offering the potential for improved survival, long-term remission, and better quality of life for patients with advanced cancers. Get a free sample of the PD-L1 Inhibitors market report with key insights and emerging therapies here: PD-L1 Inhibitors Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Download the report to understand which factors are driving PD-L1 Inhibitors epidemiology trends @ PD-L1 Inhibitors Epidemiology Forecast PD-L1 Inhibitor Drugs Uptake and Pipeline Development Activities The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the PD-L1 Inhibitors market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the PD-L1 Inhibitors pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. PD-L1 Inhibitors Market Outlook The PD-L1 inhibitors market is poised for continued growth, with PD-1/PD-L1 inhibitors expected to lead oncology drug sales in the coming years. These immuno-oncology agents have revolutionized cancer care across various tumor types and stages, from metastatic to early disease, thanks to their adaptability and durable clinical benefits. Widely adopted as monotherapy or in combination with tyrosine kinase inhibitors, chemotherapy, or other immunotherapies, PD-L1 inhibitors offer prolonged tumor responses and enhanced survival outcomes while maintaining a favorable safety profile that supports their use in broad combination regimens. While immune checkpoint inhibitors have transformed the cancer treatment landscape, efforts to target pathways beyond PD-1/PD-L1—such as TIGIT, TIM-3, and LAG-3—have met with limited success, though some agents continue development. Innovative approaches like Eftilagimod alpha (Efti), a unique MHC Class II agonist, are also gaining attention for combination strategies. In an increasingly crowded PD-L1 market, innovation and differentiation are critical. Companies must target new indications, address current treatment gaps, or become first-in-class to maintain a competitive advantage. Emerging PD-L1 inhibitors such as spartalizumab (Novartis), sasanlimab (Pfizer), zimberelimab (Arcus Biosciences), sugemalimab (EQRx/CStone), HLX10 (Henlius), and balstilimab (Agenus) are currently in development. Among the 7MM, the United States remains the largest market for PD-L1 inhibitors, generating nearly USD 26 billion in 2023, with further expansion anticipated through 2034. PD-L1 Inhibitors Market Strengths • PD-L1 inhibitors are approved for a wide range of tumor types, including non-small cell lung cancer, bladder cancer, melanoma, and more. Their use as monotherapy or in combination regimens gives them a significant advantage in oncology treatment strategies. • With numerous promising candidates in clinical development, such as spartalizumab, sasanlimab, and sugemalimab, the pipeline remains robust. Continued R&D investment ensures ongoing evolution and expansion into new indications and combinations. PD-L1 Inhibitors Market Weaknesses • The PD-L1 inhibitors landscape is crowded with multiple approved agents and late-stage candidates, making it difficult for new entrants to differentiate and capture market share without clear clinical or safety advantages. • Attempts to extend the checkpoint blockade approach beyond PD-1/PD-L1 (e.g., targeting TIGIT, TIM-3) have faced clinical setbacks. This limits expansion opportunities and raises concerns about over-reliance on the PD-1/PD-L1 axis. Scope of the PD-L1 Inhibitors Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key PD-L1 Inhibitors Companies: EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, TRACON Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and others. • Key PD-L1 Inhibitors Therapies: Sugemalimab (CS1001), Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab, HLX10, INCB099280, and others. • PD-L1 Inhibitors Therapeutic Assessment: PD-L1 Inhibitors, currently marketed, and PD-L1 Inhibitors emerging therapies • PD-L1 Inhibitors Market Dynamics: PD-L1 Inhibitors market drivers and PD-L1 Inhibitors market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • PD-L1 Inhibitors Unmet Needs, KOL's views, Analyst's views, PD-L1 Inhibitors Market Access and Reimbursement Table of Contents 1. PD-L1 Inhibitors Market Report Introduction 2. Executive Summary for PD-L1 Inhibitors 3. SWOT analysis of PD-L1 Inhibitors 4. PD-L1 Inhibitors Patient Share (%) Overview at a Glance 5. PD-L1 Inhibitors Market Overview at a Glance 6. PD-L1 Inhibitors Disease Background and Overview 7. PD-L1 Inhibitors Epidemiology and Patient Population 8. Country-Specific Patient Population of PD-L1 Inhibitors 9. PD-L1 Inhibitors Current Treatment and Medical Practices 10. PD-L1 Inhibitors Unmet Needs 11. PD-L1 Inhibitors Emerging Therapies 12. PD-L1 Inhibitors Market Outlook 13. Country-Wise PD-L1 Inhibitors Market Analysis (2020–2034) 14. PD-L1 Inhibitors Market Access and Reimbursement of Therapies 15. PD-L1 Inhibitors Market Drivers 16. PD-L1 Inhibitors Market Barriers 17. PD-L1 Inhibitors Appendix 18. PD-L1 Inhibitors Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
11 hours ago
- Globe and Mail
Opioid Withdrawal Syndrome Market Insight, Epidemiology, and Market Forecast – 2034
Opioid Withdrawal Syndrome (OWS) is a major public health concern caused by the sudden reduction or cessation of opioids in dependent individuals. Symptoms like anxiety, cramps, and severe cravings make withdrawal a key barrier to recovery. With the ongoing opioid crisis, the demand for effective, accessible treatments continues to grow. DelveInsight's ' Opioid Withdrawal Syndrome Market Report ' offers a detailed analysis of the current and projected landscape for OWS treatment across the major markets, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report outlines the evolving epidemiology, highlighting the high prevalence of opioid dependence and withdrawal cases, particularly in countries severely impacted by opioid misuse. It also examines standard clinical practices and treatment gaps, providing a strategic overview of the healthcare burden and future market potential. Current treatment regimens for OWS typically involve a combination of opioid agonists such as buprenorphine and methadone, non-opioid medications like clonidine and lofexidine, and supportive symptom-based therapies. While effective to some extent, these approaches often face challenges related to tolerability, relapse risk, and access to care. The approval of non-opioid therapies like Lucemyra (lofexidine hydrochloride) has expanded options for managing withdrawal symptoms, but broader therapeutic innovation remains limited. Newer candidates in clinical development are targeting novel pathways to reduce withdrawal intensity and improve adherence during detoxification. With rising investments in addiction research, increasing awareness around opioid misuse, and supportive policy reforms in many countries, the OWS treatment market is set to evolve significantly by 2034. DelveInsight's report captures this transformation by evaluating market dynamics, key players, emerging therapies, and regulatory landscapes. It is an essential resource for pharmaceutical companies, healthcare providers, policymakers, and investors looking to understand and capitalize on the opportunities in this high-need therapeutic area. Some of the Key Facts of the Opioid Withdrawal Syndrome Market Report: • In 2022, the Opioid Withdrawal Syndrome market in the 7MM was valued at around USD 1.3 billion and is expected to grow steadily through 2034. • Approximately 8.2 million cases of opioid withdrawal syndrome were reported in the 7MM in 2022, with a projected decline over the forecast period. • Around 9.1 million individuals had long-term opioid use in the 7MM in 2022. • The US accounted for nearly 7.1 million opioid withdrawal cases in 2022, expected to decrease by 2034. • In March 2025, Hikma Pharmaceuticals announced that Health Canada approved KLOXXADO® (naloxone HCl) Nasal Spray 8 mg for the treatment of known or suspected opioid overdose, characterized by respiratory and/or central nervous system depression, in adult patients. • In February 2025, Indivior announced that the FDA approved label changes for SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The updates include a rapid initiation protocol reducing treatment time from one week to one hour and alternative injection sites to improve flexibility and patient adherence. • In October 2024, the FDA approved Protega Pharmaceuticals' ROXYBOND™ (oxycodone IR 10 mg) for severe pain management. It is the first FDA-approved abuse-deterrent IR oxycodone designed to reduce intranasal and intravenous misuse. • Leading companies in the Opioid Withdrawal Syndrome market include atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Emerging acute Opioid Withdrawal Syndrome drugs include BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome remains a significant clinical challenge, with rising awareness and evolving treatment strategies driving demand for safer, more effective therapies to manage symptoms and reduce relapse risk. To know in detail about the Opioid Withdrawal Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Opioid Withdrawal Syndrome Market Forecast Opioid Withdrawal Syndrome Overview Opioid Withdrawal Syndrome (OWS) is a clinical condition that occurs when individuals who are physically dependent on opioids suddenly reduce or discontinue their use. This syndrome is a hallmark of opioid dependence and is driven by the neuroadaptive changes in the brain that result from prolonged exposure to opioids. When opioid use is stopped, the abrupt absence of the drug leads to a rebound of neurotransmitter activity, particularly within the noradrenergic and dopaminergic systems, triggering a range of distressing physical and psychological symptoms. Symptoms of opioid withdrawal typically begin within hours of the last dose and can vary in intensity depending on the type of opioid used, duration of use, and individual factors such as tolerance and overall health. Common early symptoms include anxiety, agitation, muscle aches, sweating, and insomnia. These may progress to more severe manifestations such as abdominal cramps, vomiting, diarrhea, dilated pupils, rapid heartbeat, and intense cravings. While not usually life-threatening, the severity of symptoms can lead to significant discomfort and increase the risk of relapse. Get a free sample of the Opioid Withdrawal Syndrome market report with key insights and emerging therapies here: Opioid Withdrawal Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Opioid Withdrawal Syndrome Epidemiology Segmentation: The Opioid Withdrawal Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Number of Opioid Misuse Cases • Number of Cases with long term Opioid usage • Total Opioid Withdrawal symptoms Cases Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Epidemiology Forecast Opioid Withdrawal Syndrome Drugs Uptake and Pipeline Development Activities The Opioid Withdrawal Syndrome drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Opioid Withdrawal Syndrome market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Opioid Withdrawal Syndrome pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Opioid Withdrawal Syndrome Market Outlook The Opioid Withdrawal Syndrome (OWS) market is expected to witness steady growth through 2034, driven by the increasing prevalence of opioid use disorder (OUD), rising awareness about withdrawal management, and expanding access to treatment services. As the opioid crisis continues to pose a significant public health burden across the globe, particularly in the United States and parts of Europe, the demand for effective withdrawal therapies is accelerating. The availability of both opioid-based and non-opioid pharmacological options, including buprenorphine and clonidine, is enhancing treatment outcomes and reducing relapse rates, contributing to market expansion. Furthermore, advancements in withdrawal management protocols, growing governmental and private sector investments in addiction care, and the development of more targeted and patient-friendly therapeutics are fueling innovation in the OWS treatment landscape. The emergence of new formulations, such as long-acting buprenorphine and novel non-opioid agents, is expected to diversify the treatment arsenal and improve patient adherence. With continued efforts toward destigmatization and the integration of mental health support, the OWS market is poised for sustained progress over the forecast period. Opioid Withdrawal Syndrome Market Strengths • Increased global awareness about the opioid crisis, coupled with supportive government policies, funding, and public health initiatives, has significantly strengthened the market. Programs promoting medication-assisted treatment (MAT) and opioid withdrawal management have expanded access to care, thereby boosting demand for therapeutic options. • The development of innovative pharmacological treatments, such as non-opioid medications (e.g., lofexidine) and extended-release formulations of buprenorphine, has improved treatment adherence and outcomes. These advancements enhance patient experience and create opportunities for differentiated products in the market. Opioid Withdrawal Syndrome Market Weaknesses • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. • Despite increasing awareness, societal stigma associated with opioid dependence continues to prevent many individuals from seeking help. Underreporting and underdiagnosis of OWS limit the true market potential and delay access to treatment. Scope of the Opioid Withdrawal Syndrome Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Opioid Withdrawal Syndrome Companies: atai Life Sciences, Medicinova, BioXcel Therapeutics Inc., and others. • Key Opioid Withdrawal Syndrome Therapies: BXCL501, MN-166, DMX-1002, and others. • Opioid Withdrawal Syndrome Therapeutic Assessment: Opioid Withdrawal Syndrome, currently marketed, and Opioid Withdrawal Syndrome emerging therapies • Opioid Withdrawal Syndrome Market Dynamics: Opioid Withdrawal Syndrome market drivers and Opioid Withdrawal Syndrome market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Opioid Withdrawal Syndrome Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal Syndrome Market Access and Reimbursement To learn more about the key players and advancements in the Opioid Withdrawal Syndrome treatment landscape, visit the Opioid Withdrawal Syndrome Market Analysis Report Table of Contents 1. Opioid Withdrawal Syndrome Market Report Introduction 2. Executive Summary for Opioid Withdrawal Syndrome 3. SWOT analysis of Opioid Withdrawal Syndrome 4. Opioid Withdrawal Syndrome Patient Share (%) Overview at a Glance 5. Opioid Withdrawal Syndrome Market Overview at a Glance 6. Opioid Withdrawal Syndrome Disease Background and Overview 7. Opioid Withdrawal Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Opioid Withdrawal Syndrome 9. Opioid Withdrawal Syndrome Current Treatment and Medical Practices 10. Opioid Withdrawal Syndrome Unmet Needs 11. Opioid Withdrawal Syndrome Emerging Therapies 12. Opioid Withdrawal Syndrome Market Outlook 13. Country-Wise Opioid Withdrawal Syndrome Market Analysis (2020–2034) 14. Opioid Withdrawal Syndrome Market Access and Reimbursement of Therapies 15. Opioid Withdrawal Syndrome Market Drivers 16. Opioid Withdrawal Syndrome Market Barriers 17. Opioid Withdrawal Syndrome Appendix 18. Opioid Withdrawal Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
11 hours ago
- Globe and Mail
Down Syndrome Market Poised for Transformation with Advancing Genetic Research and Supportive Therapies by 2034
Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by intellectual disability, developmental delays, and health issues like heart defects and thyroid problems. Advances in prenatal screening and supportive care are improving management and outcomes. DelveInsight's ' Down Syndrome Market Report ' offers a robust analysis of epidemiological trends, patient segmentation, and disease burden across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report delves into the evolving standards of care, multidisciplinary support systems, and a growing focus on cognitive enhancement therapies and comorbidity management. As research accelerates into potential disease-modifying therapies, such as neuroprotective agents and gene-targeted approaches, the Down Syndrome market is witnessing a paradigm shift. The report provides key insights into the clinical development pipeline, emerging opportunities, and strategic perspectives for stakeholders across the healthcare ecosystem. With rising awareness, policy support, and innovation in therapeutic approaches, the market outlook for Down Syndrome is expected to expand steadily through 2034. Some of the Key Facts of the Down Syndrome Market Report: • In 2023, the Down Syndrome market in the United States was valued at approximately USD 241 million. • According to the Global Down Syndrome Foundation, rare forms of the condition—translocation and mosaic Down Syndrome—account for less than 6% of cases, where not all chromosomes or cells carry the extra copy. • The prevalent population of Down Syndrome in the U.S. was estimated at around 220K in 2023. • By age group, prevalence was segmented into 0–18, 19–40, 41–60, and 60+, with the 0–18 group having the highest number of cases. • In May 2025, Darmiyan, Inc. announced FDA approval of a 7-year post-market surveillance study for BrainSee, its prognostic tool for Alzheimer's disease. The study will assess BrainSee's safety and effectiveness across a diverse U.S. population and support improved patient selection for future Alzheimer's clinical trials. • In May 2025, the FDA granted Breakthrough Device designation to Fujirebio Diagnostics' Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, an in vitro blood test for detecting amyloid plaques in adults aged 55+ showing signs of Alzheimer's disease. • In April 2025, Biogen Inc. (Nasdaq: BIIB) announced that the FDA granted Fast Track designation to BIIB080, an antisense oligonucleotide therapy targeting tau, for Alzheimer's disease treatment, aiming to speed up its development and review. • In June 2024, Eli Lilly confirms donanemab trial for Down syndrome Alzheimer's patients. In an FDA advisory meeting, Lilly's CMO, Dr. David Hyman, disclosed that a clinical study assessing donanemab safety in this population is being planned • Leading companies in the Down Syndrome market include AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, and others. • Emerging acute Down Syndrome drugs include AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others. • Growing prevalence and advancing therapies are boosting demand for more targeted Down Syndrome treatments. To know in detail about the Down syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Down Syndrome Market Forecast Down Syndrome Overview Down syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of an extra copy of chromosome 21. This chromosomal anomaly leads to a wide spectrum of physical and intellectual developmental delays and disabilities. Individuals with Down syndrome often exhibit characteristic facial features, hypotonia (low muscle tone), and varying degrees of cognitive impairment. The condition is the most common chromosomal disorder globally, with its incidence increasing with advanced maternal age. Despite its challenges, medical and social advancements have significantly improved life expectancy and quality of life for individuals with Down syndrome. Early intervention programs, inclusive education, regular health screenings, and multidisciplinary care have played a critical role in promoting their development and independence. However, individuals with Down syndrome are also at higher risk for a range of health complications, including congenital heart defects, respiratory and hearing issues, thyroid conditions, and an increased predisposition to Alzheimer's disease. Ongoing research is exploring targeted therapies to address these associated conditions and improve long-term outcomes. Get a free sample of the Down syndrome market report with key insights and emerging therapies here: Down Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Down Syndrome Epidemiology Segmentation: The Down Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Prevalent Cases of Down Syndrome • Type-specific Cases of Down Syndrome • Gender-specific Cases of Down Syndrome • Prevalent Cases of Down Syndrome by clinical manifestations • Prevalent Cases of Down Syndrome by Age Download the report to understand which factors are driving Down syndrome epidemiology trends @ Down Syndrome Epidemiology Forecast Down Syndrome Drugs Uptake and Pipeline Development Activities The Down Syndrome drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Down Syndrome market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Down Syndrome pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Down Syndrome Market Outlook The Down Syndrome treatment landscape is evolving as research delves deeper into its complex genetic and neurological underpinnings. While there is currently no curative therapy, ongoing advancements in supportive care and targeted therapeutic development are reshaping the outlook for individuals with the condition. Multiple investigational therapies, including AEF0217 and ACI-24.060, are under clinical evaluation, aiming to address cognitive impairment and other neurological symptoms associated with trisomy 21. These candidates, in early-to-mid-stage clinical trials, signal a growing focus on disease-modifying approaches. As diagnostic accuracy improves and awareness increases, early intervention and multidisciplinary management continue to be central to care. However, the significant unmet need for pharmacological treatments that go beyond symptomatic relief opens the door for innovation. With a rising global prevalence and expanding research investments, the Down Syndrome market is poised for gradual but meaningful growth through 2034, driven by breakthroughs in neurodevelopmental therapy and precision medicine. Down Syndrome Market Strengths • Increasing public health initiatives, better screening protocols during pregnancy, and early childhood diagnosis are enhancing timely interventions, improving quality of life, and creating opportunities for therapeutic development. • A growing pipeline of targeted therapies, such as AEF0217 and ACI-24.060, shows increasing pharmaceutical interest in addressing cognitive and neurological aspects of Down Syndrome, paving the way for disease-modifying treatments. Down Syndrome Market Weaknesses • Despite ongoing clinical efforts, there are currently no FDA-approved treatments that specifically address the underlying neurodevelopmental deficits of Down Syndrome, limiting clinical options. • Conducting trials in Down Syndrome populations poses challenges due to cognitive variability, ethical considerations, and difficulty in selecting appropriate clinical endpoints, which can slow drug development progress. Scope of the Down Syndrome Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Down Syndrome Companies: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, and others. • Key Down Syndrome Therapies: AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others. • Down Syndrome Therapeutic Assessment: Down Syndrome, currently marketed, and Down Syndrome emerging therapies • Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Down Syndrome Unmet Needs, KOL's views, Analyst's views, Down Syndrome Market Access and Reimbursement To learn more about the key players and advancements in the Down syndrome treatment landscape, visit the Down Syndrome Market Analysis Report Table of Contents 1. Down Syndrome Market Report Introduction 2. Executive Summary for Down Syndrome 3. SWOT analysis of Down Syndrome 4. Down Syndrome Patient Share (%) Overview at a Glance 5. Down Syndrome Market Overview at a Glance 6. Down Syndrome Disease Background and Overview 7. Down Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Down Syndrome 9. Down Syndrome Current Treatment and Medical Practices 10. Down Syndrome Unmet Needs 11. Down Syndrome Emerging Therapies 12. Down Syndrome Market Outlook 13. Country-Wise Down Syndrome Market Analysis (2020–2034) 14. Down Syndrome Market Access and Reimbursement of Therapies 15. Down Syndrome Market Drivers 16. Down Syndrome Market Barriers 17. Down Syndrome Appendix 18. Down Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
